Reports Q4 revenue $509.8M, consensus $461.05M. “2023 was another transformational year for Insulet. The rapid adoption of Omnipod 5 helped fuel our eighth consecutive year of more than 20% constant currency revenue growth,” said Jim Hollingshead, President and Chief Executive Officer. “Our team’s outstanding execution and relentless pursuit of innovation further solidify our position as the category leader, strengthen our competitive moats and enable us to deliver our groundbreaking innovation to even more people. We entered 2024 with powerful momentum and are well-positioned for continued profitable growth and value creation as we simplify life for the millions of people with diabetes around the world.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insulet gets CE Mark approval of Omnipod 5 integration with FreeStyle Libre 2
- Insulet price target raised to $208 from $163 at Stifel
- Insulet Assumes New Off-Balance Sheet Financial Obligation
- Insulet Secures Lower Interest Rates in Credit Agreement Amendment